07:43 AM EDT, 10/29/2026 (MT Newswires) -- TME Pharma (ALTME.PA) signed a deal for the proposed development and commercialization of its glioblastoma drug NOX-A12, or olaptesed pegol, with Japan's TMS Co. Specifically, the European biotech company signed a 150,000-euro six-month exclusive negotiation agreement with TMS as part of strategic options for its leading oncology asset, according to a Thursday filing. The two parties also agreed to a nonbinding term sheet for exclusive access to NOX-A12 in which TME Pharma could receive 10 million euros in upfront and near-term payments and 100 million euros in regulatory and commercial sales milestones, among others.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.